Peter Ronco, Emmes Chief Executive Officer, added: “VaxTRIALS is a highly complementary match for Emmes. It extends our global reach from our current base in North America, Europe and Asia to Latin America, one of the fastest growing regions for clinical trials due to its large, diverse patient population and high-quality clinical research sites. VaxTRIALS adds a number of new biopharmaceutical and public-private partnership clients and further strengthens one of our largest research therapeutic areas: vaccines and infectious diseases.”
VaxTRIALS’ vaccine-related clinical trials have been conducted in 11 Latin American countries, as well as the Philippines. Their trials have covered diseases such as influenza, dengue, chikungunya, hepatitis A, meningitis, norovirus, herpes zoster, pertussis, respiratory syncytial virus (RSV), polio and COVID-19.
“Another benefit for Emmes,” said Ronco, “is that we’ll be able to take advantage of VaxTRIALS’ established network in Latin America to reach clinical trial participants in our other core therapeutic areas, including rare and paediatric diseases, cell and gene therapy, and ophthalmology.”
Dr José Jimeno, VaxTRIALS CEO commented: “Both our companies have built enduring customer relationships and a legacy of service in vaccine and infectious disease research. I am proud that we have made both people and cultural development a priority, including hiring and developing employees who care deeply about making a difference in public health.
“I’m also excited to incorporate Emmes’ technology expertise, as well as legacy and depth in biostatistical analysis and data management, for the benefit of our clients throughout Latin America,” he added. “Emmes’ Advantage eClinical data management platform, with benefits including improving data quality, easing oversight of clinical trial operations, and reducing trial timelines and costs, can be extremely
helpful to our customers.”